Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biogen, Inc. (NQ: BIIB )

270.21 USD -3.63 (-1.33%)
Streaming Delayed Price Updated: 12:19 PM EST, Jan 20, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Biogen, Inc.

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
DEADLINE ALERT for TILE, BABA, and BIIB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
From GlobeNewswire News Releases
New Coalition Aims To Close The Opportunity Gap In Bioscience
Liftstream, NEVCA, Third Rock Ventures, Biogen and BioDirector build a coalition to close the opportunity gap in bioscience 
From Business Wire News Releases
The Top 3 Contrarian Stocks to Buy Right Now
When it comes to investing, thinking outside the box can have significant rewards. 
Tags MSFT BIIB Market News
From Motley Fool
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact Robert S. Willoughby at... 
From PR Newswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, JOYY, Berry Corporation, and Pinterest and Encourages Investors to Contact the Firm
From GlobeNewswire News Releases
NASDAQ:BIIB Investor Notice: Lawsuit Alleges Securities Laws Violations by Biogen Inc.
San Diego, CA -- (SBWIRE) -- 12/02/2020 -- An investor, who purchased shares of Biogen Inc. (NASDAQ:BIIB), filed a lawsuit alleged Securities Laws violations by Biogen Inc. 
From SBWire - Latest Press Releases
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen, Inc. (BIIB)
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen, Inc. (BIIB) 
From Business Wire News Releases
BIIB INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biogen Inc.
From GlobeNewswire News Releases
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Biogen, Inc. (BIIB) Investors
Glancy Prongay & Murray LLP, Leading Securities Law Firm, Announces the Filing of Securities Class Action on Behalf of Biogen, Inc. (BIIB) Investors 
From Business Wire News Releases
A Look Into Healthcare Sector Value Stocks
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that ... 
Tags General SNY Earnings
From Benzinga
Sage Therapeutics Dives On $1.5 Billion Collaboration Deal With Biogen
Biotech company Sage Therapeutics inked a $1.5 billion deal to develop two key drugs in depression treatment and movement disorders with Biogen. But Sage stock collapsed Friday on the news. 
From Investor's Business Daily
Sage Therapeutics Dives On $1.5 Billion Collaboration Deal With Biogen
Biotech company Sage Therapeutics inked a $1.5 billion deal to develop two key drugs in depression treatment and movement disorders with Biogen. But Sage stock collapsed Friday on the news. 
From Investor's Business Daily
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders
From GlobeNewswire News Releases
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders
Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced that they have executed a global collaboration and license agreement to jointly develop and commercialize zuranolone... 
From Business Wire News Releases
Zhang Investor Law Alerts Investors to Deadline in Securities Class Action Lawsuit Against Biogen Inc. – BIIB
From GlobeNewswire News Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
From GlobeNewswire News Releases
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Neovasc, Interface, and Biogen and Encourages Investors to Contact the Firm
From GlobeNewswire News Releases
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Biogen, Inc. (BIIB) Investors
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Biogen, Inc. (BIIB) Investors 
From Business Wire News Releases
LABU, BIIB, BTAI, BLUE: Large Outflows Detected at ETF
Symbols mentioned in this story: LABU, BIIB, BTAI, BLUE Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These... 
Tags ETFs
From ETF Channel
BIIB INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biogen Inc.
From GlobeNewswire News Releases
TalkMarkets Tuesday Talk: Optimism Advancing On Turkeys
Boosted by the the AstraZeneca vaccine news US markets closed higher on Monday. Encouraged by the GSA release of Presidential transition funds post-close, Tuesday market futures are trading higher. 
Tags Commodities ETFs Financial
From Blogs - TalkMarkets
Large Cap Biopharma Performance and Metrics Q3 2020; ETFs Are Winners
Surging coronavirus infections has even nicked the healthcare sector down 3% for the week. 
Tags Healthcare Pharma/Biotech Stocks / Equities
From Blogs - TalkMarkets
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Biogen, Inc. (BIIB) Investors
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Biogen, Inc. (“Biogen” or the “Company”)... 
From Business Wire News Releases
BIIB Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Biogen Inc. Investors of Class Action and Encourages Investors to Contact the Firm
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) and certain of its officers, on behalf of... 
From Business Wire News Releases
5 Value Stocks To Watch In The Healthcare Sector
Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that ... 
Tags STSA News Health Care
From Benzinga
ISD Immunotech, a Novo Seeds Portfolio Company, Enters Strategic Research Collaboration for the Development of a Novel Lupus Treatment
- Developing STING Antagonist for Treatment of Severe Lupus 
From PR Newswire
ROSEN, A TOP RANKED LAW FIRM, Reminds Biogen Inc. Investors of Important January 12 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourages Investors with Losses in Excess of
From GlobeNewswire News Releases
3 Best Pharma Stocks to Buy Right Now
These three stocks are ready to break out. 
Tags Market News REGN BIIB
From Motley Fool
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
From GlobeNewswire News Releases
BIIB INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit has been Filed Against Biogen Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of... 
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.